Neurology drugs get PBAC nod

The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the PBS listing of cladribine for the treatment of relapsing-remitting multiple sclerosis. The PBAC’s recommendation was based partly on its assessment that the cost-effectiveness of cladribine would be acceptable if it were cost-minimised against fingolimod. At its July meeting, PBAC also recommended the Authority Required listing of ...

Already a member?

Login to keep reading.

© 2021 the limbic